Dwight Moxie - Jan 31, 2024 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role: SVP, GC & Secretary
Signature: /s/ Dwight Moxie
Stock symbol: RVNC
Transactions as of: Jan 31, 2024
Transactions value $: $0
Form type: 4
Date filed: 2/2/2024, 04:48 PM
Previous filing: Sep 7, 2023
Next filing: Mar 4, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVNC	Common Stock	Award	$0	+90K	+204.24%	$0.00	134K	Jan 31, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RVNC	Performance Stock Units	Award	$0	+135K		$0.00	135K	Jan 31, 2024	Common Stock	135K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the Restricted Stock Unit shall vest in three (3) equal annual installments beginning from February 15, 2025, subject to the reporting person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
F2	The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with the Company through the vesting dates.
F3	The number of securities reported represents the maximum shares that can be earned.